• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Clinical Utility of Tumor Markers in the Management of Non-Small Cell Lung Cancer

        互联网

        539
        Non-small cell lung cancer (NSCLC), a leading cause of cancer-related death for men and women worldwide, exhibits a highly variable clinical course. Death may occur within a few weeks of diagnosis at one extreme, whereas other cases have apparently benign outcomes for periods of up to 20 years with no treatment (1 ). The current tumor-node-metastasis (TNM) staging system for NSCLC, which is based primarily on imaging studies and which serves as the principal guide for therapy, has significant limitations. For example, five-yr survival after “curative” resection for apparently localized, stage I NSCLC is only 46%, with death usually owing to recurrent or metastatic cancer (2 ). The reasons for this variability in clinical outcomes are largely unknown.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序